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OBJECTIVE: Decreased physician visits for dyspepsia were
predicted with the histamine-2 receptor antagonists (H2RA)
release to over-the-counter (OTC) status. The aim of this
study was to examine the presentation frequency for dys-
peptic complaints before and after the OTC release of the
H2RA and the self-reported effectiveness of OTC H2RA.
METHODS: Two cross-sectional surveys were used in a com-
munity sample. The patients comprised a random age- and
sex-stratified sample of 1600 ambulatory adults in 1993 and
1800 in 1997. Self-report, valid mail surveys gathered in-
formation on healthcare seeking and gastrointestinal symp-
toms in 1993 and 1997 and antisecretory use in 1997.
RESULTS: Presentation frequency for dyspepsia was 22% in
1993versus23.5% in 1997. Only 16% of chronic users of
the OTC H2RA obtained complete relief of symptomatic
episodes. Use of an OTC H2RA was highly associated with
presentation to a physician in the past year.
CONCLUSIONS: OTC H2RA infrequently provided the com-
plete relief desired by patients. Presentation frequency to
physicians for dyspeptic complaints did not change with
availability of H2RA OTC. (Am J Gastroenterol 2001;96:
673–676. © 2001 by Am. Coll. of Gastroenterology)
INTRODUCTION
Most patients with complaints of upper gastrointestinal (GI)
distress do not seek professional medical care, but opt for
self-directed treatment. Community surveys in the United
States and Europe have demonstrated that no more than 25%
of persons with dyspeptic complaints including reflux symp-
toms consulted a physician in the previous year (1, 2).
Dyspepsia sufferers will visit a physician, however, when
despite self-directed treatment, pain becomes frequent, se-
vere, long lasting, or anxiety provoking (2, 3). Approxi-
mately 2–4% of physician office visits annually have been
reported to be due to symptoms related to dyspepsia or
gastroesophageal reflux disease (GERD) (4).
Antacids have been the mainstay of self-directed dyspep-
sia treatment (3). The histamine-2 receptor antagonists
(H2RA) have been established as safe and efficacious pre-
scription treatment for acid-peptic disorders (5). Accord-
ingly, they were considered excellent candidates for an
over-the-counter (OTC) switch (6). Clinical and economic
benefits were anticipated after release of H2RA to OTC
status at half prescription strength in 1995. A decision
analysis suggested that physician visits for dyspepsia would
decrease by one million per year (7). Another decision
analysis modeled costs and indicated that at least 60% of
users need to obtain complete relief of symptomatic epi-
sodes for societal cost savings to occur (8). Published effi-
cacy data are limited (9, 10). Overall, 70% of subjects who
obtained some relief from antacids experienced complete
relief of symptomatic episodes using H2RA in the OTC
dose (10).
No data from unselected, community populations have
been reported in the 5 yr since OTC approval. Accordingly,
we examined the rate of presentation to physicians for a
dyspeptic complaint and patient reports of H2RA effective-
ness in a randomly selected, ambulatory population.
MATERIALS AND METHODS
Community surveys of GI symptoms were performed 2 yr
before and 2 yr after the OTC switch of H2RA. In Septem-
ber 1993, 800 men and 800 women aged 20–80 yr were
randomly selected from the administrative databases of Park
Nicollet Clinic (PNC) enrollees and Group Health. PNC is
a 425-physician multispecialty group serving Minneapolis,
MN, and surrounding suburbs. Group Health is a multispe-
cialty staff model HMO serving the same area. Nearly half
of PNC enrollees’ health plans were administered by Group
Health. Educational level of subjects was similar in both
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systems and all had pharmacy benefits. Those selected were
mailed a 56-question survey including the valid and reliable
Bowel Disease Questionnaire (BDQ) (11), and questions
about the influence of abdominal pain on activities, physi-
cian visits in the past year, and history of peptic ulcer
disease.
A similar survey was performed in August 1997. A total
of 900 men and 900 women aged 20–80 yr were randomly
selected from the computer database of PNC enrollees.
Those selected were mailed a 98-question survey including
a valid and reliable measure of GI tract symptoms—the
Digestive Health Status Instrument (DHSI) (12), and the
Rand Short Form-36, questions on healthcare seeking and
antisecretory use. The DHSI was derived from the BDQ
such that symptom items were the same except for minor
scaling changes in the 1993 and 1997 surveys.
Presentation rates to a physician for a dyspeptic com-
plaint and for reflux symptoms from the 1993 survey were
compared with 1997 after the data were age and gender
adjusted to 1990 State of Minnesota census data. Ax2 test
statistic was used for the comparison.
For the variables: frequency of OTC H2RA use, dosage
compliance, self-reported effectiveness, medication use,
distributions, and rates were calculated. Means and standard
deviations were calculated for age, race, and educational
level.
The DHSI was used to identify those with dyspepsia and
the reasons for OTC H2RA use. GERD was identified by
questions inquiring about heartburn or acid regurgitation.
Subjects with abdominal pain or discomfort centered in the
upper abdomen of greater than 1-month duration were con-
sidered to have dyspepsia. The six Manning criteria were
used to identify those with irritable bowel syndrome using a
cut-off of two or more criteria (13).
Factors associated with physician consultation in the past
year were examined using multivariable logistic regression
analysis. The dependent variable was presentation to phy-
sician to discuss upper abdominal pain or heartburn in the
past year. Demographic variables and factors significantly
associated with presentation on bivariate analyses were in-
corporated into the model as independent variables. These
included age, gender, educational level, use of OTC H2RAs,
prior physician visits for these complaints, DHSI subscale
scores, concern that symptoms were caused by a life-threat-
ening illness, and SF-36 physical and mental component
summaries.
The sponsor did not participate in study design, execu-
tion, or manuscript preparation.
RESULTS
Response rates and characteristics of respondents were very
similar from the 1993 and 1997 surveys (data not shown);
overall 70.6% in 1993 and 71.8% in 1997 returned the
questionnaire. Respondents had a mean age of 52.6 yr in
1993 and 51.8 yr in 1997, were predominantly white (95.2%
in 1993 and 94.8% in 1997), female (56% in 1993 and 55%
in 1997), and highly educated (94.3% and 94.8% high
school graduates, 72.9% and 73.7% postsecondary educa-
tion in 1993 and 1997, respectively). Nonrespondents were
younger (47.9 yr in 1993 and 48.3 yr in 1997) and more
likely to be male (64% in 1993 and 63% in 1997).
Prevalence of dyspepsia and heartburn was unchanged in
1993 and 1997. A total of 23.5% of respondents with dys-
pepsia reported presenting to a physician in the 1997 survey
compared with 22.0% in the 1993 survey (Table 1). A total
of 21.9% of heartburn sufferers consulted a physician in
1997 versus23.5% in 1993. These changes were not sig-
nificant. With an alpha of 0.05, and using a two-tailed test,
the study sample size had a power of 79% to detect a 5%
change and 99% to detect a 10% change.
Thirteen independent variables were entered into the lo-
gistic regression analysis. Five were significantly associated
with presentation to physicians for evaluation of upper ab-
dominal pain or heartburn (Table 2). This association was
particularly strong for OTC use. The R-square of 0.28 and
the c-statistic of 0.78 attest to the strength of the model (data
not shown).
Only 14.9% of those using OTC medication chronically
during the previous year achieved complete relief of symp-
toms (Fig. 1). An additional 27.6% reported marked, but
incomplete relief. Of the 189 who used the OTC H2RA at
least monthly, 78.3% used two or more antisecretory agents
(Table 3). A total of 10.6% (n5 20) received a prescription
antisecretory agent (prescription H2RAs, proton pump in-
hibitors, or prokinetic agent). Over half used antacids (n5
99 or 52.3%).
A total of 6.7% of persons who used OTC medications at
least monthly had symptoms limited only to the irritable
bowel syndrome. Most regular OTC medication users ex-
perienced at least monthly reflux symptoms and upper ab-
Table 1. Presentation to a Physician in the Preceding Year for
Dyspepsia or Heartburn
Mean % With Condition (CI)
1993 1997
Condition
Dyspepsia* 22.0 (17.4, 25.2) 23.5 (18.5, 27.8)
Heartburn† 23.6 (18.5, 29.4) 21.9 (17.9, 26.2)
* Experienced the complaint at least once in the previous year.
† Experienced the complaint at least once per month in the previous year.
CI 5 confidence interval.
Table 2. Factors Significantly Associated With Presentation to a
Physician in the Past Year
Variable p Value
OTC use ,0.0001
DHSI pain experience scale 0.005
Gender 0.039
Concern about fatal illness 0.047
DHSI reflux/ulcer scale 0.048
OTC 5 over the counter; DHSI5 Digestive Health Status Instrument.
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dominal pain/discomfort (75.8%); the remainder took these
medications for relief of upper abdominal pain/discomfort
without reflux symptoms. A total of 86% of those who ever
used OTC agents in the last year reported taking the med-
ication in recommended doses. Only 7% indicated they
exceeded the recommended dose.
DISCUSSION
Scant empiric data are available to examine the clinical and
economic impact of a switch to OTC status of a prescription
medication. The need for these data are especially acute for
the H2RAs as the decision to release these products to
unregulated OTC status was made when significant uncer-
tainty remained regarding optimal clinical management for
dyspepsia. Morever, there were expectations that the avail-
ability of effective agents without the need for a doctor’s
prescription would decrease physician visits and direct med-
ical expenditures for these common disorders (7).
The economic benefits of reduced physician visits sug-
gested by a decision model did not occur despite the fact that
this ambulatory population reported using these medications
for approved indications in appropriate doses (7). Another
decision model identified the threshold of complete symp-
tom relief necessary to achieve reduced societal costs of care
(8). This threshold was not reached in our population. The
multivariable analysis suggested that if anything, the avail-
ability of OTC H2RAs led patients to seek consultation with
physicians.
The approval of OTC therapy forcandidavaginitis led to
decreased physician visits and prescription medication use
(14). The acute, self-limited aspect of vaginitis combined
with effective OTC preparations account for these out-
comes. Societal economic benefit is an appropriate expec-
tation for OTC switches. Higher effectiveness than provided
by half-prescription strength H2RA will be necessary to
achieve this result for the dyspeptic disorders.
Our results lend partial support for releasing the H2RAs
to OTC status on clinical grounds. Some of the safety
concerns regarding inappropriate use and dosing seem un-
justified because in our sample respondents reported use for
approved indications and in recommended doses. Their
common and regular use suggest that they provide symp-
tomatic benefit.
We have highlighted key clinical and economic issues
related to the OTC H2RA switch, but the reader should be
mindful of some study limitations. Costs of care were not
measured. Self-report data, especially when the time frame
of observation extends for a year, may possess some inac-
curacy (15). The self-report effectiveness data were derived
from a homogeneous population where antisecretory treat-
ment was heterogeneous and not directly observed. None-
theless, these data derived from a large community-based
population are one of the few studies assessing the effec-
tiveness of an OTC transition. In addition, the prevalence
and consultation rates are similar to what has been reported
elsewhere (2).
In summary, an ambulatory population reported using the
OTC H2RAs appropriately and as commonly as antacids.
Expectations for the effectiveness of these medications do
not seem to have been met, however. As sole treatment,
complete relief was infrequently provided. The frequency of
physician visits for dyspeptic complaints seem unaffected
by the use of these medications. Physician visits are only
Figure 1. Treatment response in OTC H2RA users.





Use in previous year
Ever* 22.0 (20.1, 24.8) (277)
Chronic† 15.0 (13.3, 17.4) (189)
Chronically used medication
OTC H2RA 15.3 (13.3, 17.4) (189)
Antacid 12.6 (10.8, 14.6) (156)
Prescription H2RAs 5.0 (3.9, 6.4) (62)
Proton pump inhibitor 1.9 (0.2, 2.8) (23)
Promotility agent 0.3 (0.09, 0.8) (4)
* At least once in the previous year.
† At least once per month in the previous year.
CI 5 confidence interval; OTC5 over the counter; H2RA5 histamine-2 receptor
antagonist.
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one component of total disease-related costs; thus, the over-
all economic impact of the OTC H2RA transition is un-
known.
ACKNOWLEDGMENT
This study was supported in part by an unrestricted grant
from AstraZeneca, Wayne, Pennsylvania.
Reprint requests and correspondence:Michael J. Shaw, 3800
Park Nicollet Boulevard, St. Louis Park, MN 55416.
Received July 27, 2000; accepted Nov. 1, 2000.
REFERENCES
1. Jones RH, Lydeard SE, Hobbs FDR, et al. Dyspepsia in
England and Scotland. Gut 1990;31:401–5.
2. Talley NJ, Zinsmeister AR, Schleck AD, et al. Dyspepsia and
dyspepsia subgroups: A population-based study. Gastroenterol
1992;102:1259–67.
3. Lydeard S, Jones R. Factors affecting the decision to consult
with dyspepsia: Comparison of consulters and non-consulters.
J R Coll Gen Pract 1989;39:495–8.
4. Adami HO, Agenas I, Gustavsson S, et al. The clinical diag-
nosis of “gastritis” aspects of demographic epidemiology and
health care consumption based on a nationwide sample survey.
Scand J Gastroenterol 1984;19:216–9.
5. Feldman M. Pros and cons of over-the-counter availability of
histamine2-receptor antagonists. Arch Intern Med 1993;153:
2415–24.
6. Spiro HM. Paternalism by prescription? Drug Ther 1992;22:
135–7.
7. Oster G, Huse DM, Delea TE, et al. The risks and benefits of
an Rx-to-OTC switch: The case of over-the-counter H2-block-
ers. Medical Care 1990;9:834–52.
8. Kalish SC, Bohn BL, Avorn J. Policy analysis of the conver-
sion of histamine2 antagonists to over-the-counter use. Med-
ical Care 1997;1:32–48.
9. Gottlieb S, Decktor DL, Eckert JM, et al. Efficacy and toler-
ability of famotidine in preventing heartburn and related
symptoms of upper gastrointestinal discomfort. Am J Ther
1995;2:314–9.
10. Simon TJ, Berlin RG, Gardner AH, et al. Self-directed treat-
ment of intermittent heartburn: A randomized, multicenter,
double-blind, placebo-controlled evaluation of antacid and
low doses of an H2-receptor antagonist (famotidine). Am J
Ther 1995;2:304–13.
11. Talley NJ, Phillips SF, Melton LJ III, et al. A patient ques-
tionnaire to identify bowel disease. Ann Intern Med 1989;11:
671–4.
12. Shaw MJ, Talley NJ, Adlis SA, et al. Development of a
digestive health status instrument: Tests of scaling assump-
tions, structure and reliability in a primary care population.
Aliment Pharmacol Ther 1998;12:1067–78.
13. Manning AP, Thompson WG, Heaton KW, et al. Towards a
positive diagnosis of irritable bowel syndrome. Br Med J
1978;2:653–4.
14. Gurwitz JH, McLaughlin TJ, Fish LS. The effect of an Rx-
to-OTC switch on medication prescribing patterns and utili-
zation of physician services: The case of vaginal antifungal
products. Health Serv Res 1995;5:672–85.
15. Stewart AL, Hays RD, Ware JE Jr. Methods of constructing
health measures. In: Stewart AL, Ware JE Jr, eds. Measuring
functioning and well-being. Durham, NC: Duke University
Press, 1992:67–85.
676 Shaw et al. AJG – Vol. 96, No. 3, 2001
